Despite the success of monoclonal antibodies targeting the PD-1/PD-L1 signaling pathway, exemplified by FDA-approved drugs such as nivolumab, pembrolizumab, and tislelizumab [22], certain limitations persist, such as high immunogenicity, high production costs, and restricted tumor tissue penetration. This evidence concerns the gene PDCD1 and neoplasm.